Aerosol therapy is the approach utilized to administer medication directly into the lungs and its airways. It is primarily a suspension of the liquids of solids administered utilizing the medical device likewise inhaler. The medical device transforms the medication into the fine aerosol particles that can be inhaled or directly influenced into the airway and lungs. The most utilized inhalation medications are bronchodilators and corticosteroids. The major respiratory disorders that are presently cured utilizing aerosol therapy comprise: Asthma, COPD, Bronchiectasis, cystic fibrosis, pulmonary arterial hypertension, and infectious pulmonary syndromes. The novel macromolecular medications are taking aerosol therapy a step further and the therapy is being tested for non-respiratory diseases such as diabetes, analgesia, and thyroid as well.
According to the report analysis, ‘Aerosol Therapy Market:
Current Analysis and Forecast (2021-2027)’ states that Merck, Boehringer Ingelheim,
GlaxoSmithKline, AstraZeneca, Novartis, Teva Pharmaceuticals, Opko Health,
Omron Healthcare, Medtronic, and GE Healthcare. Countless M&As along with
partnerships have been undertaken by such players to boost their existence in
dissimilar regions.
Based on product, the aerosol
therapy market can be sectored into dry powder inhalers, metered dose
inhalers and nebulizers. Such segments can then further be sub segmented into
single dose inhalers and multi dose inhalers of dry powder inhalers;
conventional pressurized inhalers and soft mist inhalers of metered dose
inhalers; and jet nebulizers, ultrasonic wave nebulizers, and vibrating mesh
nebulizers of nebulizers. The nebulizers sector had the greatest CAGR in the
reviewed period on account of its ability of usage in all age groups. In the
past few years countless types of nebulizers have been introduced. Jet
nebulizers are most utilized in patients with pulmonary syndromes as they are
bulky and perform only with a power source.
Not only has this, presently, metered
dose inhaler majorly underwrites to the market and is projected to register the
market over the forecast duration. As per the data, COPD is third leading cause
of death and fifth leading cause of disability. Also, aspects such as
increasing pollution, improper lifestyles are the aspects that propel the
growth of the market.
North America is predicted to register
the market. Asia Pacific (mostly China and India) market is projected to grow
at a relatively fast rate over the review period. Additionally, the effect of
pollution is probable to intensify around the globe along with
industrialization of locations, and growing the number of vehicles. Therefore,
in the near years, it is predicted that the market of aerosol therapy will
increase around the globe more actively over the near future.
For More Information, refer to
below link:-
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing & Communications
Support@kenresearch.com
+91-9015378249
